1 min left

0% read

Genesis Therapeutics

Infrastructure

Software

Technology Company

Burlingame, California, USA

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery

Genesis Therapeutics

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery.

We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines.

Genesis raised its $52M Series A from top tech and biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price.

Story: techcrunch.com

We deploy our technology to accelerate a pipeline of several internal drug programs.

Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size.

Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets.

We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML/software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML and software engineers are top-notch—many graduates from MIT, UC Berkeley, and Stanford. They previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc.

We're recruiting pure ML research scientists and software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline.

Likewise, we have several openings in chemistry and biology to join our team of biotech and pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates.

Please apply on our website, or feel free to reach out via email directly: [email]

Frequently Asked Questions About Genesis Therapeutics

Genesis Therapeutics is an infrastructure company. Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery. We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines. Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Roc.

When evaluating any crypto company, check their official website, social media presence, regulatory status, and user reviews. Genesis Therapeutics is listed in our verified company directory — review their full profile for team details, founding date, and company background.

Genesis Therapeutics operates in the infrastructure sector of the cryptocurrency industry. Compare Genesis Therapeutics with other infrastructure companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Genesis Therapeutics, research their track record, verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Genesis Therapeutics is based in Burlingame, California, USA. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Genesis Therapeutics is based in Burlingame, California, USA, North America, with offices in Burlingame, California, USA, San Diego, California, USA.

Genesis Therapeutics has 58 employees.

Genesis Therapeutics Details

Genesis Therapeutics Offices (6)

Genesis Therapeutics Tags

More About Genesis Therapeutics

Work Model Details

Employees engage in a combination of remote and on-site work.

Latest from Academy

DeXe Built a DAO Platform That Actually Ships Products

DeXe (DEXE) is a no-code DAO governance protocol whose DAO Studio lets anyone deploy and run a decentralized organization using more than sixty modular, audited smart contracts. DEXE traded around $13.59 with a market cap above $1.1 billion, up roughly 386% from its February lows, while protocol TVL climbed to $1.7 billion across more than one hundred DAOs. DeXe has shipped working software where most DAO tooling projects stalled, with audits from Cyfrin, Hacken, CertiK, and Ambisafe and staking yields reported up to 102% APR. Yet the holder base has stayed near 50,000 even as capital concentrated, raising a concentration question the price has yet to resolve. Regulatory tailwinds from MiCA and proposed U.S. rules could favor auditable on-chain governance, but execution still needs user growth to back the valuation.

Archie DuttonMay 24, 2026

8m read

Altcoins

XCN

ENS

MKR

Onyxcoin Survived Collapse While Others Died

Onyxcoin (XCN) should not still exist. The protocol behind it was hacked twice through the same CompoundV2 precision bug, the second time for more than $3.8 million in September 2024, and dozens of similar forks simply died. Instead, XCN trades around $0.0049 with a $186 million market cap, 97% below its 2022 all-time high. What kept it alive was not a slick press release but a DAO that put the rebuild to an on-chain vote: new architecture, a fresh whitepaper, gas-free wallets, and the Goliath proof-of-stake Layer 1, whose mainnet went live on March 27, 2026. The catch is that shipping products and seeing them adopted are very different things. Infrastructure and price still do not match up, and a live governance proposal to end all future token unlocks could flip the supply story deflationary. For any Onyxcoin price prediction in 2026, the real question is whether the rebuilt community can generate organic demand, or whether XCN keeps trading on listing pumps and milestone hype.

Archie DuttonMay 23, 2026

9m read

Altcoins

THETA

SPX

FARTCOIN

Theta Explorer Shows the Real Network Activity Behind the Hype

Theta (THETA) gives every holder a free, real-time research tool that most never open: its public block explorer. While the market fixates on partnership announcements and price, the explorer quietly logs what actually happens on-chain - validator uptime, transaction throughput, staking concentration, and block production. This guide walks through how to read it: spotting validators that go dark for weeks, watching whether on-chain transaction volume diverges from theta coin price, and checking how concentrated stake really is across enterprise validators like Google, Samsung, Sony, and Binance. With a hard-capped supply of one billion THETA and a market cap depressed near $204.96M, the gap between on-chain usage and exchange-side price is exactly where the explorer earns its keep. The data is public and free. The skill is knowing what you are looking at.

Crypto News NavigatorMay 22, 2026

9m read